Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 6HeBV | 6HeBV27 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 27 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L, I54V, V82A | I15V, M36I, L63P, K70Q |
| >6HeBV27| 2 | codons 1-99 | clone 2 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| 7 | codons 1-99 | clone 7 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLMTQIGCTLNF >6HeBV27| 9 | codons 1-99 | clone 9 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKLIGGIGGFIKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| 10 | codons 1-99 | clone 10 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| 12 | codons 1-99 | clone 12 PQITLWQRPIVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKLIGGIGGFIKIRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| 13 | codons 1-99 | clone 13 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| 16 | codons 1-99 | clone 16 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| 17 | codons 1-99 | clone 17 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKLIGGIGGFIKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF >6HeBV27| codons 1-99 PQITLWQRPLVTIKVGGQLKEALLDTGADDTVLEEINLPGRWKPKLIGGIGGFVKVRQYD QIPIEICGHQAIGTVLVGPTPANIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |